Philip CA, et al. - Regarding their Phosphatase and Tensin homolog (PTEN) mutation status, the sensitivity of endometrial cancer cell lines to poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and BMN-673) and a phosphoinositide 3-kinase (PI3K) inhibitor (BKM-120), alone or in combination, had been analyzed. In endometrial cancer patients with PTEN mutations, targeting both PARP and PI3K could lead to improved personalized therapeutic approaches.